Novartis Announces Iptacopan Receives Breakthrough Therapy Designation from China's NMPA for PNH

According to Novartis, on March 7, Iptacopan (LNP023) capsules, an innovative drug in the clinical development stage for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), received the "Breakthrough Therapy Designation" from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).